Alnylam’s shares dip as analyst backs rival after rare disease data revealAlnylam has revealed the data that forms the basis of its filings for its latest potential rare disease Share XAlnylam’s shares dip as analyst backs rival after rare disease data revealhttps://pharmaphorum.com/news/alnylams-shares-dip-as-analyst-backs-rival-after-rare-disease-data-reveal/
Alnylam files its third RNAi drug lumasiran in rare kidney diseaseGene-silencing specialist Alnylam has completed filings in the US and EU for lumasiran, which aced a phase 3 Share XAlnylam files its third RNAi drug lumasiran in rare kidney diseasehttps://pharmaphorum.com/news/alnylam-files-its-third-rnai-drug-lumasiran-in-rare-kidney-disease/
AZ adds gene silencing tech to pipeline with Silence Therapeutics dealAstraZeneca has announced a collaboration with UK biotech Silence Therapeutics to develop gene silencing drugs for cardiovascular, renal, Share XAZ adds gene silencing tech to pipeline with Silence Therapeutics dealhttps://pharmaphorum.com/news/az-adds-gene-silencing-tech-to-pipeline-with-silence-therapeutics-deal/
Alnylam gets CHMP backing for second gene-silencing drug GivlaariAlnylam could be weeks away from getting its second RNA interference drug approved in Europe, after a CHMP Share XAlnylam gets CHMP backing for second gene-silencing drug Givlaarihttps://pharmaphorum.com/news/alnylam-gets-chmp-backing-for-second-gene-silencing-drug-givlaari/
Alnylam to file rare kidney disease drug after trial winAfter years where RNA interference research was in the doldrums, Alnylam is on a roll and is preparing Share XAlnylam to file rare kidney disease drug after trial winhttps://pharmaphorum.com/news/alnylam-to-file-rare-kidney-disease-drug-after-phase-3-win/
FDA approves Alnylam’s second RNAi drug – with $442K annual price tagAlnylam has had a second RNA interference (RNAi) drug approved by the FDA, to treat the ultra-rare disease Share XFDA approves Alnylam’s second RNAi drug – with $442K annual price taghttps://pharmaphorum.com/news/fda-approved-alnylams-second-rnai-drug/
NICE restores parity between Alnylam and Akcea on rare diseaseNICE has reversed its stance on Alnylam’s gene-silencing drug Onpattro for rare disease hereditary transthyretin-mediated amyloidosis (hATTR amyloidosis), Share XNICE restores parity between Alnylam and Akcea on rare diseasehttps://pharmaphorum.com/news/nice-restores-parity-between-alnylam-and-akcea-on-rare-disease/
NICE backs Akcea’s Tegsedi, pipping Alnylam to hATTR okayNICE has recommended that Akcea’s hereditary transthyretin-related amyloidosis (hATTR) treatment Tegsedi be made available on the NHS in Share XNICE backs Akcea’s Tegsedi, pipping Alnylam to hATTR okayhttps://pharmaphorum.com/news/nice-backs-akceas-tegsedi-pipping-alnylam-to-hattr-okay/
Alnylam to file gene-silencing porphyria drugAlnylam is to file its givosiran with regulators to treat a form of the blood disease porphyria, applying Share XAlnylam to file gene-silencing porphyria drughttps://pharmaphorum.com/news/alnylam-to-file-gene-silencing-porphyria-drug/
